Imitrex, Sumatriptan Newswire

Imitrex, Sumatriptan Newswire

Comprehensive Real-Time News Feed for Imitrex, Sumatriptan (generic).

Results 1 - 20 of 69 in Imitrex, Sumatriptan (generic)

  1. FDA Approves Device to Help Curb Cluster HeadachesRead the original story w/Photo

    Wednesday Apr 19 | WebMD

    But there's new hope for at least some patients. The U.S. Food and Drug Administration said it has approved a hand-held device to treat these attacks.

    Comment?

  2. FDA approves device to help curb cluster headachesRead the original story w/Photo

    Thursday Apr 20 | KTRE-TV Lufkin

    But there's new hope for at least some patients. The U.S. Food and Drug Administration said it has approved a hand-held device to treat these attacks.

    Comment?

  3. FDA Approves Vagus Nerve Stimulator to Treat Cluster HeadachesRead the original story w/Photo

    Tuesday Apr 18 | MSNBC

    The Food and Drug Administration approved a device on Tuesday meant to treat cluster headaches - a rare form of headache that affects mostly men. The device is a vagus nerve stimulator and it's not entirely clear how it works.

    Comment?

  4. Sumatriptan Sales, Price Analysis, & Sales Forecast Report 2017 - Research and MarketsRead the original story w/Photo

    Tuesday Apr 18 | Business Wire

    Find out the sales of Sumatriptan worldwide and by countries in North America, Europe, Japan, BRIC, and Australia. Discover the growth trends of Sumatriptan by countries, and also find out sales forecast until 2021.

    Comment?

  5. Pain Therapeutics Report (2017-2026) - Assessment of Pain & Analgesics - Research and MarketsRead the original story

    Monday Apr 17 | Customer Interaction Solutions

    Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering. This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain.

    Comment?

  6. Sarah Ivens: Five migraine cures that actually work... from Epsom salts to peppermint shampooRead the original story w/Photo

    Sunday Apr 16 | The New Zealand Herald

    Even the strongest medication offered Sarah Ivens little relief from her crippling migraines. So she took matters into her own hands - and found a combination of cures to keep the pain at bay.

    Comment?

  7. Induction of Migraine-Like Photophobic Behavior in Mice by Both...Read the original story

    Monday Apr 10 | CiteULike

    The Journal of neuroscience : the official journal of the Society for Neuroscience , Vol. 37, No.

    Comment?

  8. Depression of home cage wheel running: a reliable and clinically...Read the original story

    Saturday Apr 8 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. The development of new anti-migraine treatments is limited by the difficulty inassessing migraine pain in laboratory animals.

    Comment?

  9. Antares Pharma Set For Multiple Catalysts In 2017Read the original story w/Photo

    Tuesday Apr 4 | Seeking Alpha

    As the company fulfills its robust pipeline of FDA approvals over the next 24 months, the remaining nine months of 2017 will likely be action-packed. On 2016 year-end results announced March 14, Antares reported a year-over-year revenue gain of 14% to $52 million.

    Comment?

  10. Antares Pharma To Report Fourth Quarter And Full Year 2016 Financial...Read the original story

    Mar 5, 2017 | BioSpace

    Antares Pharma, Inc. today announced it will release its fourth quarter and full year 2016 financial results and recent operating progress before the market opens on Tuesday, March 14, 2017. Management will host a webcast and conference call at 8:30 a.m. ET on March 14, 2017 to discuss the results.

    Comment?

  11. Migraine could be treated with electrical stimulation patchRead the original story w/Photo

    Mar 2, 2017 | Medical News Today

    A wireless patch that uses electrical stimulation to block pain signals to the brain may one day replace drugs for the treatment of migraine, a new study suggests. Researchers reveal how the new device - created by therapeutic electronic company Theranica - significantly reduced migraine pain for more than 60 percent of study participants, compared with a sham treatment.

    Comment?

  12. Zosano Pharma: There Is More Upside Despite Recent Run-UpRead the original story w/Photo

    Feb 28, 2017 | Seeking Alpha

    The company's stock has been on a tear for the past week after announcing successful phase 3 results of M207 in acute migraine. Zosano Pharma is an emerging lifesciences company that is developing novel treatments for diseases using its proprietary transdermal delivery platform.

    Comment?

  13. Doug DeViat's the Gruesomely Merry Adventures of Nell Dash Set for Hudson Guild TheatreRead the original story w/Photo

    Feb 14, 2017 | BroadwayWorld.com

    THE GRUESOMELY MERRY ADVENTURES OF NELL DASH, AN IRREPRESSIBLY SENSIBLE CAPITALIST WITH A VENGEANCE is set for the Hudson Guild Theatre on Tuesday, February 28, 6:15 PM; Saturday, March 4, 8:30 PM; and Sunday, March 5, 1:30 PM. Tickets are $18 at www.brownpapertickets.com/event/2778296 .

    Comment?

  14. People's Pharmacy: Hormone treatment may not be needed after menopauseRead the original story w/Photo

    Feb 13, 2017 | Athens Banner-Herald

    I was listening to your podcast and heard you talk about a woman whose doctor "fired" her as a patient because she decided not to continue hormone replacement therapy. I, too, was fired by my wonderful ob/gyn about 15 years ago .

    Comment?

  15. Michael F. Marino Joins OptiNose AS As Chief Legal OfficerRead the original story

    Feb 8, 2017 | BioSpace

    OptiNosea today announced the appointment of Michael F. Marino as Chief Legal Officer. Mr. Marino is a seasoned executive and legal advisor with more than 15 years of experience advising public and privately-held companies in a diverse range of industries - most notably life sciences.

    Comment?

  16. Pain Therapeutics - Drugs, Markets & Companies - Analyzed for the...Read the original story

    Feb 8, 2017 | Customer Interaction Solutions

    Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering. This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain.

    Comment?

  17. OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375Read the original story w/Photo

    Jan 30, 2017 | Drugs.com

    OptiNosea today announced the U.S. Food and Drug Administration has accepted for review the company's New Drug Application for the investigational new product OPN-375. OptiNose is seeking marketing approval of OPN-375 in the U.S. for the treatment of nasal polyposis in adults.

    Comment?

  18. OptiNose AS Announces FDA Acceptance For Filing Of The New Drug Application For OPN-375Read the original story

    Jan 30, 2017 | BioSpace

    OptiNosea today announced the U.S. Food and Drug Administration has accepted for review the company's New Drug Application for the investigational new product OPN-375. OptiNose is seeking marketing approval of OPN-375 in the U.S. for the treatment of nasal polyposis in adults.

    Comment?

  19. When sleeping in separate rooms could save your marriageRead the original story w/Photo

    Jan 28, 2017 | Vanguard

    This morning, I woke up alone again, as I do every morning", said Caroline, tongue in check. She was trying to make me see the importance of separate bedrooms to some fledgling marriages.

    Comment?

  20. OptiNose AS Appoints As Chief Financial OfficerRead the original story

    Jan 26, 2017 | BioSpace

    OptiNose today announced the appointment of Keith A. Goldan as Chief Financial Officer . Mr. Goldan brings to the company more than 25 years of executive finance and operational leadership in biopharmaceutical and medical technology companies.

    Comment?